Eleanor Neal
Eleanor Neal
Details
Role
Senior Research Officer
Research area
Infection, Immunity and Global Health
Group
Asia-Pacific Health
Contact
Email
show email address
Top Publications
- Batmunkh, T, Neal, EFG, Amraa, O, Mazarakis, N, Altangerel, B, Avaa, N, Batbayar, L, Batsukh, K, Bright, K, Burentogtokh, T, et al. Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trial. 2026 view publication
- Batmunkh, T, Neal, EFG, Amraa, O, Mazarakis, N, Altangerel, B, Avaa, N, Batbayar, L, Batsukh, K, Bright, K, Burentogtokh, T, et al. Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trial. 2026 view publication
- Mazarakis, N, Toh, ZQ, Neal, E, Bright, K, Luu, S, Quah, L, Ng, YY, Nguyen, C, Hart, J, Do, LAH, et al. The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.. J Infect 90(3) : 106447 2025 view publication
- Batmunkh, T, Moore, KA, Thomson, H, Altangerel, B, Amraa, O, Avaa, N, Batbayar, L, Batsukh, K, Bright, K, Burentogtokh, T, et al. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.. Lancet Reg Health West Pac 42: 100953 2024 view publication
- Hume-Nixon, M, Ratu, T, Clark, S, Nguyen, CD, Neal, EFG, Pell, CL, Bright, K, Watts, E, Hart, J, Mulholland, K, et al. Prevention of young infant infections using oral azithromycin in labour in Fiji (Bulabula MaPei): study protocol of a randomised control trial.. BMJ Open 12(12) : e061157 2022 view publication
Page 1 of 6
Share //
